Therapy of NMO spectrum disorders.
Calcutta, India. In Ann Indian Acad Neurol, Sep 2015
Neuromyelitis optica (NMO) is an autoimmune demyelinating condition of the central nervous system often associated with aquaporin-4 (AQP4) autoantibodies manifesting as severe optic neuritis and long segment myelitis with tendency to relapse.
Plasmablast in the pathology of multiple sclerosis.
In Nihon Rinsho Meneki Gakkai Kaishi, 2014
Interestingly, an MS-like autoimmune disease neuromyelitis optica (NMO) is exclusively resistant to this therapy and mediated by IL-6-dependnet PBs via producing a disease-specific autoantibody against aquaporin 4 (AQP4) on astrocyte.
Aquaporins: important but elusive drug targets.
San Francisco, United States. In Nat Rev Drug Discov, 2014
Moreover, loss-of-function mutations in human AQPs cause congenital cataracts (AQP0) and nephrogenic diabetes insipidus (AQP2), and autoantibodies against AQP4 cause the autoimmune demyelinating disease neuromyelitis optica.
Physiological roles of aquaporin-4 in brain.
In Physiol Rev, 2013
Aquaporin-4 (AQP4) is one of the most abundant molecules in the brain and is particularly prevalent in astrocytic membranes at the blood-brain and brain-liquor interfaces.
Aquaporin water channels in the nervous system.
London, United Kingdom. In Nat Rev Neurosci, 2013
AQP4 is the principal member of this protein family in the CNS, where it is expressed in astrocytes and is involved in water movement, cell migration and neuroexcitation.
Aquaporin 4 and neuromyelitis optica.
London, United Kingdom. In Lancet Neurol, 2012
[review] The evidence that AQP4-IgG is involved in the development of neuromyelitis optica has revolutionised our understanding of the disease, yet important unanswered questions remain.